Ferring Pharmaceuticals has entered into a licensing agreement with Albireo, which was spun-out from AstraZeneca in 2008, for elobixibat, which is ready to enter Phase III development for chronic idiopathic constipation and Phase IIb development for irritable bowel syndrome with constipation...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: PharmaDeals Ltd